Pentraxin-3 is a candidate biomarker on the spectrum of severity from pre-eclampsia to HELLP syndrome: GenPE study

Pentraxin-3 has been reported as a promising biomarker of pre-eclampsia and its severity; however, available studies have small sample sizes, and analyses are not always adjusted for confounders. The aim of this study is to establish the strength of the association between maternal Pentraxin-3 level...

Full description

Autores:
Colmenares-Mejía, Claudia C.
Quintero-Lesmes, Doris C.
Bautista-Niño, Paula K.
Guio Mahecha, Elizabeth
Beltrán Avendaño, Mónica
Díaz Martínez, Luis Alfonso
Ortiz Serrano, Ricardo
Páez Leal, María Carolina
Monterrosa-Castro, Álvaro
Mesa Restrepo, Clara Maria
Monsalve, Germán
Sanín-Blair, Enrique
Saldarriaga, Wilmar
Luna, María Lucrecia
Casas, Juan P.
Serrano Díaz, Norma
Tipo de recurso:
Article of journal
Fecha de publicación:
2020
Institución:
Universidad de Cartagena
Repositorio:
Repositorio Universidad de Cartagena
Idioma:
eng
OAI Identifier:
oai:repositorio.unicartagena.edu.co:11227/20084
Acceso en línea:
https://hdl.handle.net/11227/20084
Palabra clave:
3. Ciencias Médicas y de la Salud
Pregnancy complications
Eclampsia
Childbirth - Complications
Hypertension
Pregnancy
ODS 3: Salud y bienestar. Garantizar una vida sana y promover el bienestar de todos a todas las edades
Rights
openAccess
License
https://creativecommons.org/licenses/by-nc/4.0/
id UCART2_116552695236a5d4c4214a3d5a9a33fc
oai_identifier_str oai:repositorio.unicartagena.edu.co:11227/20084
network_acronym_str UCART2
network_name_str Repositorio Universidad de Cartagena
repository_id_str
dc.title.eng.fl_str_mv Pentraxin-3 is a candidate biomarker on the spectrum of severity from pre-eclampsia to HELLP syndrome: GenPE study
title Pentraxin-3 is a candidate biomarker on the spectrum of severity from pre-eclampsia to HELLP syndrome: GenPE study
spellingShingle Pentraxin-3 is a candidate biomarker on the spectrum of severity from pre-eclampsia to HELLP syndrome: GenPE study
3. Ciencias Médicas y de la Salud
Pregnancy complications
Eclampsia
Childbirth - Complications
Hypertension
Pregnancy
ODS 3: Salud y bienestar. Garantizar una vida sana y promover el bienestar de todos a todas las edades
title_short Pentraxin-3 is a candidate biomarker on the spectrum of severity from pre-eclampsia to HELLP syndrome: GenPE study
title_full Pentraxin-3 is a candidate biomarker on the spectrum of severity from pre-eclampsia to HELLP syndrome: GenPE study
title_fullStr Pentraxin-3 is a candidate biomarker on the spectrum of severity from pre-eclampsia to HELLP syndrome: GenPE study
title_full_unstemmed Pentraxin-3 is a candidate biomarker on the spectrum of severity from pre-eclampsia to HELLP syndrome: GenPE study
title_sort Pentraxin-3 is a candidate biomarker on the spectrum of severity from pre-eclampsia to HELLP syndrome: GenPE study
dc.creator.fl_str_mv Colmenares-Mejía, Claudia C.
Quintero-Lesmes, Doris C.
Bautista-Niño, Paula K.
Guio Mahecha, Elizabeth
Beltrán Avendaño, Mónica
Díaz Martínez, Luis Alfonso
Ortiz Serrano, Ricardo
Páez Leal, María Carolina
Monterrosa-Castro, Álvaro
Mesa Restrepo, Clara Maria
Monsalve, Germán
Sanín-Blair, Enrique
Saldarriaga, Wilmar
Luna, María Lucrecia
Casas, Juan P.
Serrano Díaz, Norma
dc.contributor.author.none.fl_str_mv Colmenares-Mejía, Claudia C.
Quintero-Lesmes, Doris C.
Bautista-Niño, Paula K.
Guio Mahecha, Elizabeth
Beltrán Avendaño, Mónica
Díaz Martínez, Luis Alfonso
Ortiz Serrano, Ricardo
Páez Leal, María Carolina
Monterrosa-Castro, Álvaro
Mesa Restrepo, Clara Maria
Monsalve, Germán
Sanín-Blair, Enrique
Saldarriaga, Wilmar
Luna, María Lucrecia
Casas, Juan P.
Serrano Díaz, Norma
dc.contributor.researchgroup.none.fl_str_mv Grupo de investigación Salud de la Mujer
dc.subject.ocde.none.fl_str_mv 3. Ciencias Médicas y de la Salud
topic 3. Ciencias Médicas y de la Salud
Pregnancy complications
Eclampsia
Childbirth - Complications
Hypertension
Pregnancy
ODS 3: Salud y bienestar. Garantizar una vida sana y promover el bienestar de todos a todas las edades
dc.subject.proposal.eng.fl_str_mv Pregnancy complications
dc.subject.proposal.none.fl_str_mv Eclampsia
Childbirth - Complications
Hypertension
Pregnancy
dc.subject.ods.none.fl_str_mv ODS 3: Salud y bienestar. Garantizar una vida sana y promover el bienestar de todos a todas las edades
description Pentraxin-3 has been reported as a promising biomarker of pre-eclampsia and its severity; however, available studies have small sample sizes, and analyses are not always adjusted for confounders. The aim of this study is to establish the strength of the association between maternal Pentraxin-3 level and pre-eclampsia or HELLP syndrome. It was a case-control study. Women with pre-eclampsia or HELLP syndrome were defined as cases, and women with healthy pregnancies at term (>37 weeks) were classified as controls. Plasma concentrations of Pentraxin-3 were determined at the time of delivery by quantitative enzyme immunoassay. Associations between Pentraxin-3 and pre-eclampsia and HELLP syndrome were assessed by multinomial logistic regression. Subsidiary analysis for the time of disease onset was also carried out. Odds ratios and 95% confidence intervals are reported. A total of 1024 pregnant women were included (461 controls, 368 preeclampsia, 195 HELLP). A positive log-linear relationship was found between the top pentraxin-3 quintile and HELLP syndrome. After adjustment for confounders (maternal age, ethnicity, socioeconomic position, date and place of recruitment, family history of pre-eclampsia, smoking, body mass index at beginning of pregnancy, gestational age and multiple pregnancy), the strength of the association was higher for HELLP syndrome [OR 1.13 (95% CI 1.08; 1.18)] than for preeclampsia [OR 1.03 (95% CI 1.03; 1.10)]. No difference according to time of onset or pentraxin-3 level was found. In summary, pentraxin-3 level was associated with pre-eclampsia, but it was more strongly associated with HELLP syndrome. Longitudinal studies with a lower probability of residual confounding are necessary to improve our knowledge about the role of pentraxin-3 in pre-eclampsia.
publishDate 2020
dc.date.issued.none.fl_str_mv 2020
dc.date.accessioned.none.fl_str_mv 2025-08-22T15:52:11Z
dc.date.available.none.fl_str_mv 2025-08-22T15:52:11Z
dc.type.none.fl_str_mv Artículo de revista
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.version.none.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.coarversion.none.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.none.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.content.none.fl_str_mv Text
dc.type.driver.none.fl_str_mv info:eu-repo/semantics/article
format http://purl.org/coar/resource_type/c_6501
status_str publishedVersion
dc.identifier.issn.none.fl_str_mv 0916 - 9636
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/11227/20084
dc.identifier.eissn.none.fl_str_mv 1348 - 4214
identifier_str_mv 0916 - 9636
1348 - 4214
url https://hdl.handle.net/11227/20084
dc.language.iso.none.fl_str_mv eng
language eng
dc.relation.ispartofjournal.none.fl_str_mv Hypertension Research
dc.relation.citationendpage.none.fl_str_mv 8
dc.relation.citationstartpage.none.fl_str_mv 1
dc.relation.references.none.fl_str_mv Ronsmans C, Graham WJ. Maternal mortality: who, when, where, and why. Lancet. 2006;368:1189–200.
Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367:1066–74
Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol. 2013;170:1–7.
Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005; 365:785–99.
Levine R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Ph D. Circulating angiogenic factors and the risk of preeclampsia. N. Engl J Med. 2004;350:672–83.
Borzychowski AM, Sargent IL, Redman CWG. Inflammation and pre-eclampsia. Semin Fetal Neonatal Med. 2006;11:309–16.
dc.rights.uri.none.fl_str_mv https://creativecommons.org/licenses/by-nc/4.0/
dc.rights.license.none.fl_str_mv Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)
dc.rights.coar.none.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.accessrights.none.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc/4.0/
Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer Nature
dc.publisher.place.none.fl_str_mv Japan
publisher.none.fl_str_mv Springer Nature
institution Universidad de Cartagena
bitstream.url.fl_str_mv https://repositorio.unicartagena.edu.co/bitstreams/7915dd93-c34a-447f-8464-2bed039a38aa/download
https://repositorio.unicartagena.edu.co/bitstreams/dddc3acd-1b3d-461e-8db5-c54e6b0453ea/download
https://repositorio.unicartagena.edu.co/bitstreams/bf60e9e6-5f53-4e60-af94-e2700d2bd5e1/download
https://repositorio.unicartagena.edu.co/bitstreams/964a0501-1af8-4903-a0b1-98f5218890c3/download
bitstream.checksum.fl_str_mv 25b04232ac0311ee5c40369d98feacb0
64eb6cdbc122cfe492fa78c8434a0f6b
b4b66ffd7d39c776ace53ffe9dc3cd6c
aecd09a027cfebd36f1a8670293d0939
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Biblioteca Digital Universidad de Cartagena
repository.mail.fl_str_mv bdigital@metabiblioteca.com
_version_ 1851053437157900288
spelling Colmenares-Mejía, Claudia C.Quintero-Lesmes, Doris C.Bautista-Niño, Paula K.Guio Mahecha, ElizabethBeltrán Avendaño, MónicaDíaz Martínez, Luis AlfonsoOrtiz Serrano, RicardoPáez Leal, María CarolinaMonterrosa-Castro, ÁlvaroMesa Restrepo, Clara MariaMonsalve, GermánSanín-Blair, EnriqueSaldarriaga, WilmarLuna, María LucreciaCasas, Juan P.Serrano Díaz, NormaGrupo de investigación Salud de la Mujer2025-08-22T15:52:11Z2025-08-22T15:52:11Z20200916 - 9636https://hdl.handle.net/11227/200841348 - 4214Pentraxin-3 has been reported as a promising biomarker of pre-eclampsia and its severity; however, available studies have small sample sizes, and analyses are not always adjusted for confounders. The aim of this study is to establish the strength of the association between maternal Pentraxin-3 level and pre-eclampsia or HELLP syndrome. It was a case-control study. Women with pre-eclampsia or HELLP syndrome were defined as cases, and women with healthy pregnancies at term (>37 weeks) were classified as controls. Plasma concentrations of Pentraxin-3 were determined at the time of delivery by quantitative enzyme immunoassay. Associations between Pentraxin-3 and pre-eclampsia and HELLP syndrome were assessed by multinomial logistic regression. Subsidiary analysis for the time of disease onset was also carried out. Odds ratios and 95% confidence intervals are reported. A total of 1024 pregnant women were included (461 controls, 368 preeclampsia, 195 HELLP). A positive log-linear relationship was found between the top pentraxin-3 quintile and HELLP syndrome. After adjustment for confounders (maternal age, ethnicity, socioeconomic position, date and place of recruitment, family history of pre-eclampsia, smoking, body mass index at beginning of pregnancy, gestational age and multiple pregnancy), the strength of the association was higher for HELLP syndrome [OR 1.13 (95% CI 1.08; 1.18)] than for preeclampsia [OR 1.03 (95% CI 1.03; 1.10)]. No difference according to time of onset or pentraxin-3 level was found. In summary, pentraxin-3 level was associated with pre-eclampsia, but it was more strongly associated with HELLP syndrome. Longitudinal studies with a lower probability of residual confounding are necessary to improve our knowledge about the role of pentraxin-3 in pre-eclampsia.application/pdfengSpringer NatureJapanHypertension Research81Ronsmans C, Graham WJ. Maternal mortality: who, when, where, and why. Lancet. 2006;368:1189–200.Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367:1066–74Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol. 2013;170:1–7.Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005; 365:785–99.Levine R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Ph D. Circulating angiogenic factors and the risk of preeclampsia. N. Engl J Med. 2004;350:672–83.Borzychowski AM, Sargent IL, Redman CWG. Inflammation and pre-eclampsia. Semin Fetal Neonatal Med. 2006;11:309–16.https://creativecommons.org/licenses/by-nc/4.0/Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)http://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessPentraxin-3 is a candidate biomarker on the spectrum of severity from pre-eclampsia to HELLP syndrome: GenPE studyArtículo de revistainfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/article3. Ciencias Médicas y de la SaludPregnancy complicationsEclampsiaChildbirth - ComplicationsHypertensionPregnancyODS 3: Salud y bienestar. Garantizar una vida sana y promover el bienestar de todos a todas las edadeshttps://www.grupodeinvestigacionsaluddelamujer.com/ORIGINAL67_PENTRAXINA EN PREECLAMPSIA.pdf67_PENTRAXINA EN PREECLAMPSIA.pdfapplication/pdf611729https://repositorio.unicartagena.edu.co/bitstreams/7915dd93-c34a-447f-8464-2bed039a38aa/download25b04232ac0311ee5c40369d98feacb0MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81802https://repositorio.unicartagena.edu.co/bitstreams/dddc3acd-1b3d-461e-8db5-c54e6b0453ea/download64eb6cdbc122cfe492fa78c8434a0f6bMD52TEXT67_PENTRAXINA EN PREECLAMPSIA.pdf.txt67_PENTRAXINA EN PREECLAMPSIA.pdf.txtExtracted texttext/plain36255https://repositorio.unicartagena.edu.co/bitstreams/bf60e9e6-5f53-4e60-af94-e2700d2bd5e1/downloadb4b66ffd7d39c776ace53ffe9dc3cd6cMD53THUMBNAIL67_PENTRAXINA EN PREECLAMPSIA.pdf.jpg67_PENTRAXINA EN PREECLAMPSIA.pdf.jpgGenerated Thumbnailimage/jpeg14617https://repositorio.unicartagena.edu.co/bitstreams/964a0501-1af8-4903-a0b1-98f5218890c3/downloadaecd09a027cfebd36f1a8670293d0939MD5411227/20084oai:repositorio.unicartagena.edu.co:11227/200842025-08-23 05:01:27.342https://creativecommons.org/licenses/by-nc/4.0/open.accesshttps://repositorio.unicartagena.edu.coBiblioteca Digital Universidad de Cartagenabdigital@metabiblioteca.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